Allos Therapeutics Appoints Marc Graboyes as Vice President, General Counsel
13 Octobre 2004 - 3:00PM
PR Newswire (US)
Allos Therapeutics Appoints Marc Graboyes as Vice President,
General Counsel WESTMINSTER, Colo., Oct. 13 /PRNewswire-FirstCall/
-- Allos Therapeutics, Inc. (NASDAQ:ALTH) today announced the
appointment of Marc Graboyes as Vice President, General Counsel,
effective October 11, 2004. Mr. Graboyes was most recently with
Cooley Godward LLP, where he was a senior associate in the firm's
Business department and served as outside legal counsel to Allos
for nearly five years. He will report directly to the Company's
President and Chief Executive Officer, Michael E. Hart, and will
serve as a member of Allos' Management Team. "We're excited to
welcome Marc to Allos," said Michael E. Hart, President and Chief
Executive Officer of Allos. "As a longtime advisor to the Company,
Marc has an intimate understanding of the issues facing our
business and industry. We expect he will play a significant role in
helping to shape our future strategic direction." Mr. Graboyes
brings over eight years of experience in counseling public and
private technology companies in all aspects of their formation and
development. During his tenure at Cooley Godward, he developed
extensive expertise in public and private financings, mergers and
acquisitions, corporate governance and securities law disclosure
and compliance matters. Prior to joining Cooley Godward, Mr.
Graboyes served as a business associate at several other national
firms, including Perkins Coie LLP, LeBoeuf, Lamb Greene &
MacRae LLP and Arnold & Porter LLP. Mr. Graboyes earned his law
degree from the University of Colorado School of Law, where he
graduated in the top 10% of his class and was a member of the law
review. He also received his B.S. in Entrepreneurship & Small
Business Management from the University of Colorado at Boulder.
About Allos Therapeutics, Inc. Allos Therapeutics, Inc. is a
biopharmaceutical company focused on developing and commercializing
innovative drugs for improving cancer treatments. The company's
lead clinical candidate, EFAPROXYN(TM), is a synthetic small
molecule that has the potential to sensitize hypoxic (oxygen
deprived) tumor tissues and enhance the efficacy of standard
radiation therapy. In addition, Allos is developing PDX
(pralatrexate), a novel small molecule cytoxic injectable
antifolate (DHFR inhibitor) intended to treat non- small cell lung
cancer, mesothelioma and non-Hodgkin's lymphoma. For more
information, please visit the company's web site at:
http://www.allos.com/. DATASOURCE: Allos Therapeutics, Inc.
CONTACT: Jennifer Neiman, Manager, Corporate Communications of
Allos Therapeutics, +1-720-540-5227, Web site:
http://www.allos.com/
Copyright
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Allos Therapeutics, Inc. (MM) (NASDAQ): 0 recent articles
Plus d'articles sur Allos Therapeutics (MM)